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Abstract
Hematopoiesis is the complex differentiation process involving the formation of all
blood cells from a common progenitor; the hematopoietic stem cell. Errors in this process
can lead to acute leukemia, or a rapid accumulation of immature blood cells which hinders
proper immune function. While survival rates of this devastating disease have increased
dramatically over the last several decades, certain cytogenetic abnormalities remain risk
factors for treatment resistance and relapse. One of these abnormalities is a chromosomal
translocation involving the transcription factor, AF10
Mix-Lineage Leukemia, Translocated to, 10 (MLLT 10, referred to as AF10) is
involved in several oncogenic translocations involved in high-risk leukemia. Functionally
characterized as a cofactor of the histone methyltransferase, DOT1L, the extent of AF10
function has not been determined. Examination of AF10 structure and interaction partner,
b-Catenin, has lead us to develop a hypothesis regarding the role of AF10 in canonical Wnt
signaling. Wnt is a highly complex signaling pathway which plays roles in cell fate
determination and self-renewal, and is thought to be vital for the onset and progression of
leukemia. We hypothesize that the AF10 fusion protein, CALM-AF10, impacts the normal
AF10-b-Catenin interaction, and acts to dysregulate Wnt signaling as a mechanism for
promoting leukemia.
We have developed a luciferase reporter system in HEK293T cells by which to test
this hypothesis, and utilize immunoprecipitation to investigate the interaction between
CALM-AF10 and b-Catenin. We determine through the work of this thesis, that CALMAF10 upregulates Wnt signaling in a manner independent of an interaction with b-Catenin.
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Chapter 1. A literature review of AF10 and Wnt Signaling

Introduction
Each highly specified, functional member of the hematopoietic system is derived
from a common progenitor: the hematopoietic stem cell (HSC) (reviewed in [1, 2]). HSCs
have an indeterminate self-renewal capacity and give rise to progeny which become
committed to the lymphoid or myeloid pathways, before terminally differentiating into
functional members of the circulatory system [3-5]. This process is highly dependent on
growth factors and transcription factors (TFs) which regulate gene expression patterns and
facilitate these steps of commitment and differentiation [6-8]. Hematopoiesis is tightly
regulated to enable expansion and maintain homeostasis within the circulatory system
throughout development, normal cell turnover and injury [9]. Alterations of this balance
lead to malignancies of the blood; e.g.: acute leukemia [4, 10, 11]. Leukemias can occur
when a genetic alteration disrupts the normal activity of these transcription factors,
hindering normal differentiation and allowing for the accumulation of additional mutations
in a clonally expansive fashion [12]. Such disruptions go undetected until the malignant
cells overtake the bone marrow, impair production of the normal white blood cells, red
blood cells, and platelets, and lead to symptoms related to pancytopenia [12].
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Figure 1: Schematic representation of AF10 (MLLT10) translocation partners. (A) AF10 structure and consistently
retained portions. PZP: PHD finger, Zn-knuckle, extended PHD finger; NLS: Nuclear localization signal; AT: AT
hook; OM/LZ: Octa-peptide/leucine zipper; Q-rich: Glutamine rich. Arrows and numbers indicate known nucleotide
break points of AF10 [13]. (B) Retained portion of KMT2A [14]. MBD: Menin-binding domain; AT: AT hook; SNL:
Speckled nuclear localization domain; RD: Repression domain. (C) Retained portion of PICALM [15]. ENTH: AP180
N-terminal homology domain; TAD: Trans-activating domain; NES: Nuclear export signal; CBD; Clatrin-binding
domain. (D) Retained portion of XPO1 [16]. I-N-t: Importin N-Terminal. (E) Retained portion of NUP98 [17]. GLFG:
Glycine-leucine-phenylalanine-glycine motif. (F) Retained portion of HNRNPH1 [18]. RRM: RNA-recognition motif.
(G) Retained portion of DDX3X [18]. EIM: EIF4E interacting motif. (H) Retained portion of NAP1L1 [19]..

Abnormal cytogenetics can predispose a cell towards a malignant phenotype.
Chromosomal translocations, which occur when two neighboring chromosomes undergo
mid-gene double stranded breaks and are repaired to the incorrect gene, are one such
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cytogenetic abnormality that can lead to the development of leukemia [20, 21]. If the
chromosomal rearrangement occurs in-frame, translocations can lead to the transcription
and translation of a fusion protein which can retain, lose or alter functions of both partners
[22]. Because of nuclear constraints of higher order chromatin structure and the existence
of chromosomal territories, these translocations can recur non-randomly and often involve
transcription factors [23, 24].
Mix-Lineage Leukemia Translocated To, 10 (AF10, commonly referred to as AF10)
is one such transcription factor that is found frequently translocated in acute lymphoblastic
and acute myeloid leukemia, leading to the transcription and translation of a fusion protein.
AF10 has up to seven different translocation partners found in leukemia to date (Figure 1)
[15-19, 25]. Because TFs are among the factors which balance the tightly regulated process
of hematopoiesis, genes dictating differentiation can go unchecked [26]. Per the “two-hit
hypothesis”, the development of full-blown leukemia will often occur only after two or
more genetic insults. While a leukemogenic translocation may be the sole cytogenetic
abnormality present, it can lead to an in increase in mutation burden of a pre-leukemic cell
[27-30]. This results in accumulation of additional mutations within the immature
precursor cell population, which expands through clonal evolution [28]. While the
reciprocal translocations do occur, the lack of consistent appearance in AF10-translocated
leukemias minimizes the likelihood that they play major roles in transformation [31, 32].
These oncogenic translocations can thus be the initiating event of leukemia, followed by
additional genetic events that promote transformation [22, 33, 34]. Alternatively, a
translocation can act as a cooperating mutation to a pre-existent and benign mutation load
present in an immature hematopoietic cell [35]. Despite the mechanism of transformation,
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the resulting heterogeneous mutation burdens complicate research efforts in the
development of specified, targeted therapies in leukemia [36, 37]. A more complete
understanding of these transforming cytogenetic abnormalities leading to leukemogenesis
is required. AF10 is frequently translocated in leukemia, but the role it plays in normal
hematopoiesis is not well characterized. This review will summarize what is known about
wild type AF10 in the context of hematopoiesis, and shed light on how its dysregulation
through chromosomal translocation leads to the development of leukemia.

AF10 structure
Transcription factors are modular proteins with DNA-interacting segments and other
domains for recruiting effector proteins [8]. AF10 functions as a transcription factor that
interacts directly with DNA, the histone complex and other transcription factors through
its five described domains [38].
AF10 has an N-terminal PHD finger, zinc knuckle, and an extended PHD finger
(PZP) domain [39]. These two PHD fingers are collectively referred to as a leukemiaassociated-protein finger (LAP-finger) and have been shown to mediate protein-protein
interactions and homo-oligomerization of recombinant AF10 in vitro [38, 39].
Accumulating

evidence

of

homo-oligomerization

allows

for

speculation

that

oligomerization of AF10 is intrinsic to its function. In 2000, Linder et al. performed many
biochemical assays which forms the foundation of our current understanding of AF10 [38].
Using FLAG-tagged, full-length AF10, they observed a higher molecular weight species
after crosslinking immunopurified samples with ethylene glycol bis(succinimidyl
succinate) (EGS). These results were affirmed with size-elution chromatography and
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electron microscopy, indicating that pure AF10 can form tetramers in solution. In 2007,
Forissier et al. determined that this homo-oligomerization in vitro, as well as the
transactivation potential of AF10, was enhanced by the interaction between AF10 and
follistatin-related gene (FLRG) [40]. Most recently, Song et al. suggests that the DOT1LAF10 dimer forms a tetramer complex which is critical for wild type AF10 function [41].
The PZP region also senses and interacts with unmodified H3K27 within the
histone complex, as both acetylation and methylation of H3K27 inhibit this contact [42].
AF10 is therefore targeted to a poised histone where it can recruit effector proteins to
catalyze alterations to the histone, modulating transcription epigenetically [43].
AF10 binds type-C cruciform DNA via AT-hook motif, a structure-specific
interaction consistent with the role of AF10 in regulating gene expression and replication
[38, 44]. To allow for the regulation of AF10 function via specific localization within the
cell, there are three putative bipartite nuclear localization signals (NLS). Of these, Linder,
et al. determined that the most N-terminal NLS is responsible for nuclear targeting [38].
Multiple groups have confirmed a nuclear localization of AF10 with immunofluorescence,
however an early publication showed the presence of AF10 in both cytoplasmic and nuclear
extracts by western blot. [45-48].
Perhaps the most well characterized domain of AF10 is the highly conserved
octapeptide motif (EQLLERQW), followed by a partially conserved leucine zipper, known
as the OM/LZ domain [49, 50]. This motif is responsible for interaction of AF10 with
several protein partners, such as DOT1L, IKAROS, and GAS41 [45, 51, 52]. This domain
is necessary and sufficient for AF10 to induce leukemogenesis [50, 53], as will be
explained later in this review. Classically, leucine zippers facilitate dimerization or higher
5

order oligomerization and DNA binding [41, 54]. As briefly mentioned, the OM/LZ
domain of AF10 has been well documented in its interaction with DOT1L, and has been
shown to facilitate the formation of AF10-DOT1L heterodimers in vitro [41]. These recent
studies were performed with constructs consisting only of the OM/LZ domain of AF10 and
individual coiled-coil domains of DOT1L, have shown that oligomerization occurs
between the leucine zipper domain of AF10 and coiled-coil regions of DOT1L [41]. It has
not been determined if full length AF10 and DOT1L form these heterodimers in vivo,
whether this would occur via the PHD or OM/LZ domain of full length AF10, nor how this
regulates AF10 function.
Finally, there is an insufficiently characterized glutamine rich region located on the
C terminus of AF10 [38]. Q-rich regions are commonly found in eukaryotic transcription
factors and play a role in regulating their activity [55].

AF10 interacting partners
The structural domains of a transcription factor dictate its function. Transcription factors
cannot facilitate alterations in gene expression independently, but must interact with other
protein partners to modulate the epigenetic state of gene targets [8]. Although a
comprehensive understanding of AF10 target genes is unknown, we can gleam invaluable
insight as to its role in hematopoiesis and development through examination of its known
interacting partners [56].
The most well characterized cofactor of AF10 is Disruptor of Telomeric Silencing
1-Like (DOT1L), the sole mammalian histone methyltransferase of H3K79 [57]. Okada et.
al. discovered the interaction between AF10 and DOT1L in 2005, initially linking
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dysregulated DOT1L activity to Hoxa upregulation in leukemia [52]. Functionally, DOT1L
catalyzes the addition of one, two, or three methyl groups onto H3K79 within the
nucleosome. Notably, this residue is unique in the way it is modified within the histone
core, instead of the more commonly modified histone tail residues [57]. Interestingly,
DOT1L does not contain a SET domain as other histone methyltransferases do, and instead
binds S-adenosyl methionine (SAM) to act as a methyl donor [57]. Deshpande et. al.
showed that AF10 is required for DOT1L recruitment to target genes and the further
methylation of H3K79me1, but not the initial methylation of H3K79 [58]. While DOT1L
can partner with other proteins to facilitate methylation of H3K79, AF10 is responsible for
the large majority of this complex’s function [58, 59]. The coiled-coil domain within
DOT1L interacts with the OM-LZ domain of AF10, an interaction stabilized by zinc [41].
Loss of AF10 – and disruption of the AF10-DOT1L interaction – results in a genome-wide
decrease in H3K79me2 and H3K79me3, correlating with a decrease in genomic stability
and disrupted hematopoiesis, mirroring the effects of loss of DOT1L [58, 60, 61].
To date, the relationship between DOT1L and AF10 is the most studied aspect of
wild type AF10. However, AF10 interacts with multiple proteins, and the role it plays in
other contexts needs to be considered as well to fully elucidate AF10 function. Many AF10
interacting partners are known to be involved in regulating both higher order chromatin
structure, the DNA damage response, and the Wnt signaling pathway, so we should
consider that AF10 may function in these cellular processes.
The evidence indicating the role of AF10 in higher order chromatin structure stems
from studies highlighting protein interacting partners that are well established in this
regard. GAS41, TIP60, and IKAROS are all the currently known interacting partners of
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AF10 that play a role in regulating gene expression on a macro level through chromatin
remodeling ATPase complexes [51, 62, 63].
AF10 interacts with GAS41, a documented epigenetic reader, sensitive to
succinylation on histone H3K122, as well as acetylation on H3K27 and H3K14 [64].
Initially determined to interact with AF10 by a yeast-two-hybrid screen, the interaction was
confirmed with GST-fusion pull-down, immunoprecipitation and subsequent western blot
of endogenous protein from KG1a cells, and co-localization of endogenous protein via
immunofluorescence [51]. Functionally, GAS41 has been shown to recruit the p400 and
SRCAP chromatin remodeling complexes to histone H2A, partially facilitating the
exchange of H2A with H2A.Z [64]. GAS41 also interacts with INI1, a core subunit of the
SWI/SNF chromatin remodeling complex [51]. These large, multi-subunit ATP-dependent
chromatin remodeling complexes are responsible for chromatin remodeling in the
regulation of gene expression and the DNA damage response, and are frequently
dysregulated in cancers [65, 66]. Aside from the study where this interaction was identified,
the relationship between AF10 and GAS41, or AF10 and SWI/SNF, has not been
investigated further. However, there is additional evidence suggesting that AF10 interacts
with TIP60, the histone acetyltransferase (HAT) and catalytic subunit of the p400 SWR1class ATPase chromatin remodeling complex [67]. Overexpressed TIP60 interacts with
recombinant KMT2A-AF10, but not a KMT2A-AF10 construct containing a C-terminal
AF10 deletion, implicating that AF10 interacts with TIP60. However, this was not verified
with full-length AF10 in a purified context, so it could be that GAS41 mediates this
interaction, or the binding could be dependent on the fusion protein itself. Regardless of
whether it is a direct or indirect interaction with TIP60, this begins the evidence implicating
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AF10 in hematopoiesis through chromatin remodeling. Adding depth to this observation is
the interaction between AF10 and the transcription factor, IKAROS.
IKAROS is a Zn-finger transcription factor has been extensively studied in myeloid
and lymphoid development [68, 69]. IKAROS is essential for proper hematopoietic
commitment and maturation, which is of great interest seeing as AF10 function in
hematopoietic cell development is not well characterized. [70]. Heterozygous expression
of a dominant negative form of IKAROS (IK6) leads to the development of leukemia in
mice [71-73]. Like DOT1L and GAS41, IKAROS interacts with the OM/LZ domain of
AF10 [45]. IKAROS regulates target genes through modification of higher order chromatin
structure, specifically through interaction with the Mi-2/NuRD (majority) and SWI/SNF
(minority) chromatin remodeling complexes [62]. These complexes can activate or repress
transcription by loosening or compacting chromatin structure, respectively, based on
cellular context and cell cycle status [62].
Another manner by which AF10 is implicated in maintaining higher order
chromatin structure is through the Polycomb Repressive Complex (PRC), which maintains
transcriptional repression at target genes. Perrin et al. examined the role of Alhambra (Alh),
the Drosophila homologue for human AF10, in mediating Polycomb group Repressive
Element (PRE) activation. They concluded that the leucine zipper domain activates several
PREs, an effect which is inhibited by the N-terminal PHD domains in the full-length
protein [74]. Based on AF10 interacting with both GAS41 and IKAROS, implicated in
chromatin remodeling, and with PREs in Drosophila, there is a need for further studies to
determine how loss of wild type AF10 independently impacts higher order chromatin
structure. Furthermore, there are additional molecular implications, such as within the
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DNA damage response, based on AF10 interacting partners which need to be considered
in speculating wild type AF10 function.
The interactions with Gas41 and Tip60 subsequently introduce the role of AF10
and DOT1L in the DNA damage response (DDR) [65]. Chromatin remodeling is vital for
proper detection and repair of DNA double stranded breaks (DSB) [75]. SWI/SNF is
largely responsible for destabilizing histone complexes after DNA damage, which unpacks
heterochromatin, allowing for detection of the DSB and for repair proteins to be recruited
[76]. P400/TIP60 is recruited to DSB via the scaffolding protein MDC1, and is required
for the recruitment of repair proteins BRCA1 and 53BP1 via RNF8 chromatin
ubiquitination [63, 65]. 53BP1 is recruited to and directly interacts with H3K79me2 as a
critical requirement of ionizing radiation (IR)-induced DNA damage during G1/G2 phase
[74]. Interestingly, H3K79me2 is required for proper restart of transcription after DNA
damage repair, and this associates DOT1L in both the initiation and resolution of the DDR
[77, 78]. Global reduction in H3K79me3 and H3K79me3 lead to genomic instability,
which is an important aspect of leukemogenesis [79]. Although DOT1L is well established
as a critical part of the DNA damage response, MLLT10 has not been studied directly in
this context.
Markedly, the protein partners of AF10 described thus far indicate a macro-level
mechanism of AF10 function. Data suggests that there are interacting partners that
implicate AF10 in a micro-level of regulation as well, by the transcription of individual
target genes and ability to oligomerize. Follistatin Related Gene (FLRG), an interacting
partner of AF10, is highly homologous to Follistatin and is involved in gonad development,
bone formation, and human hematopoiesis [80, 81]. FLRG, unlike Follistatin, is present in
10

the nucleus and acts to modulate the activity of several members of the Transforming
Growth Factor-beta (TGF-b) superfamily, several of which are implicated in hematological
malignancy [82, 83]. FLRG itself has been linked to the regulation of hematopoiesis,
originally cloned as a translocation partner of CCND1 in a case of B-cell chronic
lymphocytic leukemia [40]. FLRG binds the PZP region of AF10, and association increases
the propensity of AF10 to oligomerize, and upregulates transcription of AF10 target genes
[84]. Using recombinant AF10, Forissier et al. speculates that homo-oligomerization may
provide a platform for co-activator recruitment to AF10 target genes, and FLRG may act
to regulate this process [84]. One major limitation to the literature describing AF10 is the
lack of a comprehensive understanding of these direct target genes. However, one set of
genes where AF10 is known to localize are Wnt/b-Catenin target genes, through a direct
interaction between AF10 and b-Catenin [85].
AF10 is required for canonical Wnt/b-Catenin transcription by its recruitment to
TCF/b-Catenin target genes in a b-Catenin dependent manner. In this publication,
Mahmoudi et al. reasoned that the role of AF10 was to recruit DOT1L to the TCF/b-Catenin
target genes allowing for the methylation of local H3K79me1 and subsequent
transcriptional elongation of these gene targets [85]. However, further studies have
observed the role of DOT1L specifically in Wnt-dependent transcription using DOT1L
inhibitors and found that methylation of H3K79 is dispensable for transcription of Wnt/bCatenin target genes [86, 87]. This poses the possibility that AF10 is acting in a manner
independent of DOT1L, perhaps structurally, to provide a foundation for other activating
cofactors, or as a modulator of higher order chromatin structure, making it indispensable
for Wnt/b-Catenin transcription. It is worth noting that the context of this study was in
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intestinal cells, and has not been followed up with in the context of hematopoiesis or
leukemia. Further studies should parse out the role of AF10 in Wnt signaling, as Wnt
signaling has subtle, yet major implications in the onset and progression of leukemia [8890]. Additionally, it would be of great interest to explore other major developmental
pathways which may rely on AF10 for proper regulation.
Collectively, these data implicate AF10 in higher order chromatin structure and the
DNA damage response via interaction with chromatin remodeling complex-associated
proteins, GAS41, IKAROS, DOT1L and perhaps TIP60. Further, AF10 is implicated in
regulation of individual gene expression through its interaction with DOT1L, FLRG, and
in transcription of Wnt target genes through interaction with b-Catenin.

A role for AF10 in early development
To fully elucidate the function of a transcription factor, its target genes need to be
identified. While the expanse of AF10 target genes has not yet been fully determined, it is
highly implicated in the expression of genes tightly regulated and essential during
development and embryogenesis. In mice lacking full-length AF10, death occurs between
E13.5 and E16.5 due to malformed vasculature [60]. In this same publication, Ogoh et. al.
determined that AF10 is implicated in regulating the proliferation of neural progenitor cells
within the forebrain of mice, through modifying the expression of the neural crest gene,
AP2a. This gene is a target of AF10 that is downregulated after embryogenesis, consistent
with a role of AF10 in early tissue specification and differentiation [60]. AP2a has been
shown to alter osteogenic differentiation through regulation of the Frizzled1 receptor,
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indicating a role for this gene in the composition of the bone marrow microenvironment
and thus, hematopoietic development [91, 92].
Work by Chamorro-Garcia et. al. indicates that as hematopoietic cells undergo
differentiation, AF10 expression decreases and cells become less sensitive to changes in
AF10 expression [93]. Hematopoietic cell lines that have not yet committed to a defined
myeloid lineage undergo apoptosis when levels of AF10 are altered through overexpression
or knockdown. After promoting differentiation of these cell lines with 12-OTetradecanoylphorbol-13-acetate (TPA), AF10 levels decreased and the differentiated
megakaryocytes or monocytes lost their sensitivity to alterations in AF10 [93]. This allows
for speculation that a specific role for AF10 may be more identifiable at the level of
uncommitted, immature hematopoietic cells, and that deviations from tight regulation are
highly consequential in these progenitors [93]. Linder et. al. identified that within the testes,
AF10 is expressed highly in post-meiotic germ cells, between stages VI and VIII [48].
Additionally, they observed AF10 in white matter of the cerebellum. The conclusions from
this body of work indicated that AF10 may be involved in negatively regulating
proliferation, as its expression is highest in cells that are not actively dividing during
development [94].
The Hox gene-cluster represents four gene sub-clusters, A-D, composed of
homeodomain-containing transcription factors vital for dorsal-ventral spatiotemporal
patterning and proper embryonic development [95, 96]. The Hoxa genes are of particular
interest in hematopoiesis as they regulate the hematopoietic differentiation program; they
are expressed highly in early hematopoietic progenitor cells and undergo downregulation
after differentiation [97]. Expression of Hoxa genes is dependent on DOT1L and higher
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methylation states of H3K79, and the role of AF10 in recruiting DOT1L to this locus has
been established [58, 98, 99]. Deshpande et. al. determined that H3K79me2 and
H3K79me3 are lost as hematopoietic cells mature, and this early, highly-methylated
epigenetic profile requires AF10. Proper expression of the Hoxa genes is therefore
dependent on AF10, and tight regulation of the Hoxa genes is essential for appropriate
hematopoietic development [58, 100, 101].
The interacting partners of AF10 implicate this protein in developmental regulation as well.
Both GAS41 and TIP60 are highly involved in the maintenance and identity of embryonic
stem cells [64, 102]. The knockdown and knockout of GAS41 via shRNA and CRISPRCas9 respectively, lead to a loss of pluripotency in mouse embryonic stem cells [64].
Another interacting partner, FLRG, is highly expressed at day 7 of embryogenesis in mice,
with a sharp decrease after this timepoint [40]. Similarly, Wnt/b-Catenin signaling is a
temporally regulated pathway that can dictate cell fate. Long-term, slow dividing human
HSCs express the Frizzled-6 receptor, and many diverse Wnt ligands are present within
bone marrow and primitive hematopoietic tissue during embryogenesis [103-107]. With
this evidence, altered AF10 activity has vast implications in embryogenesis and
hematopoiesis through its interaction with these factors, and further studies are needed to
better understand the specific role it has throughout embryonic development and progenitor
cell maintenance.
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AF10 in leukemia
In contrast to the paucity of information regarding wild type AF10, the role of AF10 in
leukemogenesis through participation in oncogenic chromosomal translocations is very
well described. To date it has been cloned as a fusion partner to seven different genes, all
found in acute lymphoblastic and acute myeloid leukemia (ALL and AML) (Table 1) [1519, 25].
Table 1: AF10 fusion partners and their functions
Fusion Partner

Gene Symbol

Aliases

Leukemia Subtype

Frequency of MLLT10 Translocation

Association with HOXA
upregulation

Function of fusion partner

Phosphatidylinositol Binding
Clathrin Assembly Protein

PICALM

CALM, CLTH, LAP

T-ALL, AML

10% of T-ALL (Ansafi, 2003)
6-7% of T-ALL (Abdelali, 2013)

Proof of causation
(Caudell, 2007; Okada, 2006;
Deshpande, 2006)

Regulates the size and shape of
endocytic vesicles

Histone-lysine Nmethyltransferase 2A

KMT2A

HRX, MLL1, TRX1, CXXC7, ALL1

AML, ALL

8% of all MLL rearranged leukemias
(Meyer, 2017)

Proof of causation
(Okada, 2015)

Histone methyltransferase, positive
regulator of gene transcription

Exportin-1

XPO1

CRM1

T-ALL

1 patient (Bond, 2014)

Correlation

Regulates the export of nuclear
cargo

Nucleoporin 98

NUP98

ADIR2, NUP96, NUP196, NUP98-96

Atypical myelodysplastic
syndrome resembling
chronic myelomonocytic
leukemia

1 patient (Soler, 2013)

Correlation

Regulates transport of
macromolecules between nucleus
and cytoplasm

Heterogenous nuclear
ribonucleoprotein H1

HNRNPH1

HNRPH

ETP-ALL

1 patient (Brandimarte, 2013)

Correlation

RNA binding proteins: associate with
heterogenous nuclear RNA: provides
substrate for processessing premRNAs

DEAD-Box Helicase 3 Xlinked

DDX3X

HLP2, DEAD/H BOX-3, MRX102, DDX14

T-ALL

3% T-ALL (Brandimarte, 2014)

Correlation

DDX3X is ubiquitously expressed, in
ATP-dependent DEAD box RNA
helicase family.

Nucleosome Assembly
Protein 1 Like 1

NAP1L1

NRP, HNRP, NAP-1-Related Protein

ETP-ALL, T-ALL

3 patients (Bond, 2015)

Correlation

Plays a role in nucleosome
formation, chromatin formation and
DNA replication

The AF10 translocations for which enough data is available, namely KMT2A-AF10,
CALM-AF10 and NUP98-AF10, are mainly associated with poor prognosis [108-110].
AF10 was first discovered in 1995 by Chaplin et. al. as a fusion partner of the highly
promiscuous Lysine Methyltransferase 2A (KMT2A), as the participating gene in the
t(10;11)(p12;q23) translocation. It was initially believed that retained features of KMT2A
were the driving source of leukemogenesis, until AF10 was found independently fused to
CALM; a protein involved in regulating the size and shape of endocytic vesicles [15, 111].
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Interestingly, CALM has also been found independently fused to KMT2A in leukemia
[112].
KMT2A-AF10 is found in approximately 15% and 3% of KMT2A-rearranged AML and
ALL respectively, and is characterized by a complex rearrangement [113, 114]. KMT2A
is oriented centromere to telomere whereas AF10 is oriented the opposite direction,
necessitating multiple breakpoints and inversions to occur for an in-frame translocation
between the two genes [115]. KMT2A-AF10 is primarily found in infant leukemia (ALL
and AML), and pediatric AML, but may also be present in pediatric and adult ALL [108].
CALM-AF10 is primarily found in T-ALL, and less commonly in AML [108, 116]. The
remaining five observed translocations involving AF10 are present in T-ALL and early Tcell precursor (ETP)-ALL [16-19]. Despite this heterogeneity of leukemic subtype, there
are commonalities between each translocation and each leukemia involving AF10. Shortly
after AF10 was cloned as a fusion partner to KMT2A, it was determined that the leucine
zipper was consistently retained in the translocations; a finding that has held true as the
remaining translocation partners of AF10 have become known [49, 50, 53]. In 2002,
DiMartino et. al. recognized that the leucine zipper was the minimal domain required and
sufficient for transformation of CALM-AF10 and KMT2A-AF10 translocated leukemias,
and this domain is consistently retained in each AF10 translocation leading to the
development of leukemia [50].
All AF10 translocations lead to the upregulation of the proto-oncogenic, distal Hoxa cluster
genes and HOX cofactor, MEIS1 [19, 28, 117, 118]. This is due to aberrant recruitment of
AF10 to the Hoxa gene locus, although the specific mechanism of this occurrence may
vary between translocation partners and is not fully understood. The retained OM/LZ
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domain of AF10 within the translocated fusion protein recruits DOT1L to the Hoxa cluster,
activating gene transcription by the addition of methyl groups onto H3K79me1 [58, 98].
The Hoxa genes have been shown to play a strong transformative role in leukemogenesis.
For example, overexpressing Hoxa9 leads to a block in differentiation and expansion of
the hematopoietic stem cell population, but is unable to induce leukemia on its own [119,
120]. Co-overexpression of the HOX cofactor, MEIS1, facilitates this oncogenesis. Sun,
et. al. recently showed that this is reflective of MEIS1 co-binding with HOXA9 at several
enhancer regions of known oncogenic regions [121]. In fact, Meis1 is overexpressed in
CALM-AF10 leukemias along with the Hoxa genes [28, 122].
As briefly mentioned, the mechanism of localization of AF10 fusion partners to the
Hoxa genes varies based on the fusion partner present. KMT2A is a histone
methyltransferase of H3K4, and maintenance of Hoxa gene expression is dependent on this
protein [123]. Although the SET domain of KMT2A, which catalyzes methylation of
H3K4, is lost in the fusion, the chromatin binding domains of KMT2A are consistently
retained [14]. This then localizes KMT2A-AF10 to the Hoxa locus, allowing DOT1L
recruitment and methylation of H3K79 to drive high expression of these genes [124]. This
mechanism is different from what was determined to drive CALM-AF10 localization to
the Hoxa genes.
In 2011, Deshpande et. al. determined that the clathrin binding domain of CALM
fused to the OM/LZ domain of AF10, was required and sufficient for transformation of
mouse bone marrow cells in vitro and in vivo [53]. Conway, et. al. expanded this research
and further determined that only the nuclear export signal (NES) of CALM was required
for immortalization of murine hematopoietic progenitor cells in vitro, and upregulation of
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Hoxa genes [46]. The mechanism of this phenomenon is two-fold. First, it was determined
that this NES interacts with nuclear export protein, Exportin-1 (XPO1). This interaction
facilitates the nuclear export of most of the CALM-AF10 fusion protein, leading to the
global hypomethylation of H3K79 and genomic instability. Conway et. al. additionally
performed Chromatin Immunoprecipitation qPCR (ChIP-qPCR) to determine that XPO1
binds chromatin at the Hoxa locus, and this interaction recruits the remaining nuclear
CALM-AF10 through the retained NES of CALM [47, 117]. Interestingly, several other
AF10 fusion partners have domains through which a similar mechanism of Hoxa activation
can be speculated.
Interaction with XPO1 is a common feature of many of the fusion partners of AF10.
NUP98 and DDX3X both interact directly with XPO1, which could be a uniting
mechanism of how the fusions are localized to the Hoxa locus [125, 126]. In addition, the
direct XPO1-AF10 chromosomal translocation has been found in a patient with T-ALL
[16]. The remaining two fusion partners, HNRNPH1 and NAP1L1, both have nuclear
localization signals and their mechanism of transformation has not been explored in detail
[18, 19].
It is important to note that, while Hoxa upregulation is identified in a relatively
large percentage of all leukemias, AF10 rearranged leukemias maintain a unique gene
signature within the Hoxa upregulated leukemias [127]. By developing and performing
RNA-sequencing in tetracycline-inducible cell models of KMT2A-AF10 and CALM-AF10,
Chen, et. al. describe specific gene targets and molecular pathways of these two AF10
fusion proteins [128]. One hundred and sixty-eight common genes were deemed targets of
KMT2A-AF10 and CALM-AF10, including the Hoxa cluster genes and Meis1, as well as
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Flt3, Cd34, Gfi1b, Eya1, and Nkx2-3 [128]. Altered Jak-Stat and NFkB signaling were also
observed as upregulated pathways in the presence of both AF10 translocations, and it
would be of great interest to see if these commonalities hold true with the remaining fusion
partners of AF10.
Given the essential nature of DOT1L in Hoxa expression in these leukemias, DOT1L
inhibitors have been a primary source of targeted therapy development [99]. These have
seen great success in reversing Hoxa expression patterns and even leukemia onset in preclinical in vitro and in vivo research, however, minimal efficacy and significant drug
resistance has been observed in clinical trials involving KMT2A rearranged leukemia [129,
130]. While much is known about the mechanism of leukemic transformation and
maintenance, much remains unknown. This necessitates a more foundational
understanding of the factors at play in AF10-rearranged leukemia, including a complete
understanding of normal AF10 function in hematopoiesis.

Wnt signaling
Wnt/b-Catenin signaling is a major determinate of cell fate, and plays major roles
in tissue homeostasis and injury repair, embryonic development, and maintenance of stem
cells [131]. It also functions to control cell migration, polarity, differentiation and
apoptosis. There are two major subsets of Wnt signaling, namely “canonical” and “noncanonical”. The former, which will be the focus of this work, involves signal activation of
b-Catenin, resulting in downstream transcription of b-Catenin/TCF/LEF target genes. The
latter encompasses the downstream processes of Wnt stimulation which are independent
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of TCF/LEF target gene transcription, and include the planar cell polarity and Wnt-calcium
pathways [131, 132].
Transcriptional activation of Wnt/b-Catenin target genes depends largely on the
action of the destruction complex. This complex regulates b-catenin availability in the
nucleus, through the combined action of five different proteins. Axin and adenomatous
polyposis coli (APC) are both tumor suppressors, acting as scaffolding for b-Catenin and
the Ser/Thr kinases, glycogen synthase kinase 3 (GSK3) and casein kinase 1 (CK1) [133].
When the destruction complex is in the cytoplasm (in the absence of a Wnt stimulus), bCatenin associates with the scaffolding elements. CK1 and GSK3 then sequentially
phosphorylate Ser45, Thr41, Ser37 and Ser33, which allows the E3 ubiquitin ligase, bTrCP, to bind and target b-Catenin for proteosomal degradation [133]. B-catenin associated
cofactors within the nucleus, such as members of the T-cell factor (TCF) and lymphoid
enhancer factor (LEF) families, are co-bound by repressors. The most well-known of these
are Groucho/Transducin-like enhancer of split (Gro/TLE), and they keep transcription of
these genes repressed in the absence of a Wnt ligand [134].
There are nineteen known Wnt ligands and ten Frizzled (Fzd), seventransmembrane-span protein receptors. Together with co-receptors, antagonists, and
unique cellular context, the variability of the Wnt signaling pathway results in a highly
diverse and context-dependent downstream effect [135]. To stimulates canonical Wnt
signaling, a ligand interacts with Fzd and co-receptor, LRP5/6. The binding of a ligand to
the receptor complex causes the recruitment of Axin to the cytoplasmic tail of LRP5/6,
translocating the destruction complex away from cytoplasmic b-Catenin [131]. The
interaction of a Wnt ligand with Fzd and LRP5/6 also induces the activation of cytoplasmic
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Dishevelled (Dsh), which plays a role in dictating the fate of the transduced signaling
pathway [136]. No longer phosphorylated, b-Catenin accumulates in the cytoplasm and
enters the nucleus in a manner that has yet to be defined [137]. It then replaces repressive
cofactors at TCF/LEF target genes, thereby initiating transcription.

Wnt signaling is altered in leukemia
Many aspects are involved in whether a leukemia will be resistant to treatment. The bone
marrow microenvironment (BMME) contains many factors that can cause resistance, by
providing a protective and proliferative environment for the immature leukemia stem cells
[138]. Growth factors secreted by MSCs within the BMME can lead to the propagation and
retention of leukemic stem cells within this niche, resulting in a highly aggressive leukemia
[138]. For example, MSCs secrete CXCL12, which interacts with the leukemic surface cell
receptor CXCR4 and stimulates pro-survival pathways, while facilitating the homing of
leukemic cells to the BMME [139]. Other signaling pathways within the BMME, such as
Wnt/b-Catenin signaling, are less well characterized. However, emerging evidence
suggests that Wnt signaling is critically involved in the development and maintenance of
leukemia [90, 140].
For example, active b-Catenin was shown to be required for the development of
AML in mouse models [141]. In other instances, AML has been characterized by
epigenetic alterations to Wnt genes; CpG island methylation of Wnt inhibitor genes
silences the expression of certain Wnt inhibitors, and this methylation is indicative of poor
prognosis [88, 89, 142, 143]. The AML-ETO translocation, which leads to the development
of AML, has been shown to induce expression of b-Catenin through direct induction of the
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plakoglobin promoter [144]. Additionally, in this study, inhibition of Wnt/b-Catenin
signaling through expression of a dominant negative TCF was sufficient to inhibit growth
of a cell line with an endogenous AML-ETO translocation [144]. Another study found that
increased b-Catenin protein levels was correlative with clonogenicity and self-renewal of
leukemia cells, and predictive of poor overall and event-free survival [145]. It was reported
that even leukemia cells which do not express b-Catenin as measured by RT-PCR or
western blot, show induction of b-Catenin after stimulation with Wnt3a. This is significant
because this response to Wnt3a is lost in the normal, differentiated hematopoietic
counterparts [145].
While leukemias do not generally show blatantly activating mutations in bCatenin/Wnt signaling, the alterations in this signaling pathway are much subtler. It
becomes important then, to understand what is happening mechanistically within leukemia
cells that they retain this dependence on and sensitivity to b-Catenin, while the downstream
effects of Wnt signaling promote leukemogenesis and resistance to treatment.
Unfortunately, contradicting evidence exists within the literature of the downstream effects
of canonical Wnt stimulation in leukemia cells. One study found that stimulation with
Wnt3a lead to the inhibition of proliferation in B-ALL cell lines, whereas another study
provided evidence in direct disputation of that claim [146, 147]. There remains much
unknown about the role canonical Wnt signaling plays in the onset and progression of
leukemia.
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Chapter 2. Hypothesis, Experimental Set-up, and Results: CALM-AF10 and Wnt
Signaling

Rationale for the Hypothesis
AF10 interacting partners are dysregulated in the presence of CALM-AF10. While
DOT1L is the most well-studied example of this, there are other factors that are altered by
CALM-AF10 which perpetuate disease severity. For example, the cellular localization of
IKAROS is altered by CALM-AF10, and given the vital role of IKAROS in T-cell
development, this carries implications for altered IKAROS activity in CALM-AF10
leukemia [45, 148, 149]. While evidence supports DOT1L mislocalization as the widelyaccepted mechanism for transformation of CALM-AF10 leukemias, current clinical trials
utilizing DOT1L inhibitors have been largely unsuccessful in treating patients with similar
DOT1L-dependent, HOXA-upregulated leukemias [99, 130]. This is despite highly
promising preliminary pre-clinical data showing eradication of HOXA leukemias in mice
treated with these drugs [150, 151]. This highlights the need for a more thorough
understanding of the pathways altered in this high-risk leukemia, to develop more effective
treatment options for patients.
As alluded to previously, Wnt signaling is another aspect of leukemogenesis that is
coming to be appreciated. It is unknown how the CALM-AF10 oncoprotein affects Wnt
signaling. Mahmoudi et. al. determined that the C-terminus of b-Catenin directly interacts
with the N-terminus of AF10 via GST-pulldown in their study of murine intestinal cells
[85]. However, the N terminus construct of AF10 was broadly designed to include
everything N-terminal to the OM/LZ domain, and the specific interaction domain was not
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further narrowed down (Figure 2). This introduces two main questions: Is the interaction
between b-Catenin and CALM-AF10 retained? Additionally, is Wnt signaling altered by
CALM-AF10? We hypothesize that the presence of CALM-AF10 alters the function
of b-Catenin, and perturbs Wnt target gene transcription.

Figure 2: AF10 (MLLT10) N-terminus interacts with C-terminal of b-Catenin. Figure from Mahmoudi, et al 2010.
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CALM has been shown to have a transactivation domain, capable of upregulating
transcription of genes bound by CALM-AF10, separately from AF10 in epigenetic
modification of H3K79 – leading to transcriptional activation [152]. This all but ensures
that any part of the genome bound by CALM-AF10 will be highly expressed. Therefore,
we hypothesize that if CALM-AF10 maintains the interaction with b-Catenin, we would
expect any Wnt signal to result in amplified downstream transcription of Wnt/b-Catenin
target genes.
Conversely, the CALM-AF10 translocation leaves only one allele of AF10 intact.
This leads to haploinsufficiency of the protein and can negatively affect the activity of wild
type AF10 by limiting the availability of AF10 in the nucleus. This is exemplified by a
global decrease in H3K79me2/me3 in CALM-AF10 leukemias. Without AF10 in sufficient
quantities, DOT1L is not properly localized to DNA and the resulting genomic instability
ensues. CALM-AF10 may additionally have a directly negative effect on AF10 function
and target gene expression, through dominant negative inhibition of wild type AF10
directly, sequestering its activity.
Aside from DOT1L, this dominant negative effect is also observed with AF10
fusion partner IKAROS. Even though IKAROS retains its function in the presence of
CALM-AF10, its mislocalization by CALM-AF10 away from the nucleus prevents it from
regulating gene targets [45]. AF10 forms tetrameric complexes in vitro, and this interaction
has recently been determined to rely on the OM/LZ domain of AF10 [41]. As this domain
is consistently retained in AF10 fusion proteins, it becomes likely that CALM-AF10
interacts with wild type AF10 in a manner yet to be documented. In this sense, we would
expect that the loss of interaction between CALM-AF10 and b-Catenin would result in
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downregulation of Wnt/b-Catenin target genes, by a dominant negative action of CALMAF10 with wild type AF10. As there is minimal practicality of testing and manipulating
CALM-AF10 in an endogenous setting, which would take into consideration the single
intact allele of AF10 and endogenous levels of CALM-AF10, we can design an artificial
system to observe the effects of recombinant CALM-AF10 on Wnt signaling. The two
experimental aims this thesis will address are the following: Whether the interaction
between AF10 and b-Catenin is retained in the context of CALM-AF10; and what happens
to Wnt-mediated transcription in the presence of CALM-AF10.
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Results

Characterizing the interaction between AF10 and b-Catenin in leukemia
The interaction between AF10 and b-Catenin has been established in intestinal cells,
proving AF10 essential for proper Wnt signaling and thus, intestinal homeostasis. This
interaction has not been shown in the context of hematopoiesis, so we first sought to
confirm this interaction in leukemia cells. The Kasumi-1 cell line, derived from a sevenyear-old

male

diagnosed

with

acute

myeloblastic

leukemia,

was

used

for

immunoprecipitation of AF10 before immunoblotting for b-Catenin. Preliminary results
indicate that AF10 may have coimmunoprecipitated with b-Catenin in this cell line (Figure
3a). This was the result of one biological replicate, and previous experiments had also
provided evidence to support the hypothesis that AF10 and b-Catenin interact in
hematopoietic cells. However, in these early experiments, the control blot for the
immunoprecipitated protein was not included, and thus, not suitable for inclusion in this
body of work (data not shown). From these results, we can state that AF10 and b-Catenin
likely interact in hematopoietic cells, and further studies are necessary to confirm this
interaction.
We next sought to answer the question of whether b-Catenin interacts with CALMAF10. Our CALM-AF10 construct has an N-terminal FLAG tag, so we transiently
transfected HEK293T cells with CALM-AF10 and MIE. With the cell lysate, we pulled
down CALM-AF10 with an anti-FLAG antibody. Western blots were immunoblotted for
b-Catenin and CALM-AF10, and indicate that there is no interaction observed between bCatenin and CALM-AF10 in this manner (Figure 3b). Importantly, the interaction between
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AF10 and b-Catenin is well established in HEK293T cells [85]. The result of our
experiment, stemming from one biological replicate, suggests that the interaction between
CALM-AF10 and AF10 does not occur, but again, further experiments and optimization
of this pull-down are required before conclusions can be drawn. The converse
immunoprecipitation of b-Catenin and immunoblot of CALM-AF10 will also be necessary.
The increased rigor provided by these future experiments will add validity to the current
hypothesis that b-Catenin and CALM-AF10 do not interact. However, the results at hand
can be utilized to generate a hypothesis regarding the role of CALM-AF10 on the
transcriptional response to Wnt stimulation; this is addressed in the discussion. We then
tested what effect the lack of interaction between CALM-AF10 and b-Catenin would have
on cells’ response to an external Wnt ligand.

Figure 3: The interaction between AF10 and b-Catenin is lost in CALM-AF10. (A) Kasumi-1 cell immunoprecipitation
of AF10 and IgG, immunoblot for AF10 and b-Catenin. (B) Pull-down of FLAG-CALM-AF10 in HEK293T cells
transiently transfected with either FLAG-CALM-AF10 or MIE empty vector, immunoblot for CALM-AF10 and b-Catenin.
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CALM-AF10 has a Positive Effect on Wnt-Mediated Transcription
To measure the effect of CALM-AF10 on Wnt-mediated transcription, we utilized
Human Embryonic Kidney 293T (HEK293T) cells and an established, lentiviral Wnt
reporter plasmid (7xTFP, figure 4A) [153]. HEK293T cells have an intact Wnt/b-Catenin
signaling system, however it is not constitutively active and requires stimulation with a
Wnt ligand to activate Wnt signaling. The 7xTFP plasmid expresses a luciferase gene
downstream from a 7xTCF binding site, so when Wnt signaling is activated and b-Catenin

Figure 4:Lentiviral 7xTFP plasmid to determine Wnt transcription levels. (A) 7xTFP reporter cassette design, figure
from Fuerer, et al (2010). (B) Dose-response curve indicating increasing luciferase expression in response to
increasing concentrations of Wnt3a (x-axis, 50-200 ng/mL) at 6, 18 and 24 hours in HEK293T-7xTFP cells. Vehicle
control is the equal volume of PBS + 0.1% BSA as compared to the volume of Wnt3a added to cells.
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is in the nucleus, luciferase is transcribed in levels dependent on the amount of ligand
present (Figure 4B) [153]. This plasmid houses a puromycin resistant gene downstream a
SV40 promoter, ensuring constitutive puromycin resistance for selection and maintenance
of cells containing the reporter plasmid. Unlike other Wnt reporter plasmids which rely on
transient transfection, e.g. the TOPFLASH/FOPFLASH reporter system, this stably
integrated plasmid sidesteps the variability between transfection efficiency within each
experiment [153, 154]. We created monoclonal cell lines of HEK293T cells with the 7xTFP
plasmid (HEK293T-7xTFP) to correct for the variable amount of plasmid introduced into
each cell during the initial transduction (Figure 5). This allowed for consistency in reporter
expression levels between conditions within experiments, as well as consistency between
experiments. The experiments in this thesis study were performed with clone B12.
We stimulated the HEK293T-7xTFP cells with the Wnt3a ligand for twenty-four
hours. This ligand stimulates canonical Wnt signaling, and additionally it is found in the
bone marrow [155]. Thus, Wnt3a represents a physiological Wnt ligand that hematopoietic
cells would find in situ, allowing this experimental design to identify downstream
alterations in response to a physiologically relevant ligand. The time of exposure and
concentration of 100 ng/mL was chosen based on the dose-response curve represented in
figure 4B. This concentration ensured adequate stimulation of the Wnt signaling pathway,
without nearing a saturation level that may mask a positive or negative effect from the
CALM-AF10 fusion protein.
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Figure 5: Isolation of monoclonal HEK293T-7xTFP cell lines. Luciferase activity is measured in 10 clones of 293T cells
stably transduced with 7xTFP, after growing clones from limiting dilution. All colonies demonstrate very low levels of
baseline luciferase expression without stimulation of Wnt3a, and varied yet significant increase in luciferase reporter
expression after 24 hours of stimulation with 200 ng/mL of Wnt3a.

To ensure the system was capable of reflecting alterations in transcription from the
addition of the fusion protein, we utilized a dominant negative TCF4 (TCF4∆N31)
construct, lacking the b-Catenin binding domain. Upon transfection and stimulation, we
would expect Wnt signaling to decrease, as b-Catenin can no longer bind to and activate
the mutated TCF [156]. Luciferase expression of this condition would not be directly
compared to the luciferase expression in the other two conditions, namely MSCV-IRESeGFP-CALM-AF10 (CALM-AF10) and the MSCV-IRES-eGFP (MIE) empty vector, but
would be used to validate our system.
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The experimental procedure was as follows, with greater detail in the material and
methods section (Figure 6). HEK293T-7xTFP cells were plated on day 0. 24 hours after
plating, cells were transfected with 0 µg, 0.5 µg, 1 µg, and 2 µg CALM-AF10, balanced
by MIE empty vector to result in 2 µg total DNA and consistent amounts of DNA
introduced into each condition. 4 µg of TCF4∆N31 was added because it would not be
directly compared to the other conditions, but was optimized separately to ensure that this
control worked appropriately. 24 hours after transfection, cells were stimulated with Wnt3a
or PBS + 0.1% BSA vehicle control. Wnt3a remained in the media for 24 hours before

Figure 6: Schematic describing the experimental setup of the luciferase assay. Day 0, Wnt reporter cells were plated in
six-well plate before transfection with plasmid constructs on day 1. Twenty-four hours after transfection, cells were
treated with 100 ng/mL Wnt3a or a vehicle control (PBS + 0.1% BSA). Twenty-four hours after stimulation, 5x105 cells
were carefully counted and harvested for luciferase expression, and the remainder harvested in protein lysis buffer for
western blot analysis.

harvest, according to the dose and time curve (Figure 4B). Cells were meticulously
counted, and 5x105 cells were harvested from each condition for luciferase assay. The
remaining cells were harvested for protein analysis and western blot. Wnt3a stimulated
condition results from the Luciferase Reporter Assay Kit (Biovision) were normalized to
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the vehicle control conditions, and all transfected conditions were again normalized to the
parental control.
The results from three biological replicates indicate that the presence of CALMAF10 increases the Wnt transcription response to an external Wnt3a ligand (Figure 7).
Importantly, the results indicate a robust decrease in transcription in the presence of
TCF4∆N31, validating that our system is working as expected. As indicated by western
blot, levels of CALM-AF10 reflect a high transfection efficiency with some variation in
the relative amount of CALM-AF10 entering the cell.
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Figure 7: CALM-AF10 leads to upregulated Wnt signaling in HEK293T-7xTFP cell lines. (A) Luciferase levels in
transfected HEK293T-7xTFP cells after transfection with increasing amounts of CALM-AF10 (x-axis) and harvest.
Asterisk indicates statistical significance of p < 0.005. Luciferase levels (y-axis) of Wnt3a-treated cells was normalized
to vehicle control. Resulting levels were normalized to parental control. (B) Western blot representation of transfections,
levels of CALM-AF10 and GAPDH.
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Chapter 3: Discussion
CALM-AF10 and b-Catenin do not appear to interact
AF10 interacts with b-Catenin through the N-terminus of AF10 [85]. We have provided
evidence to support that this interaction occurs in a malignant hematopoietic cell line, as it
has only been shown in intestinal cells in the literature. It is unknown whether the
interaction is retained between b-Catenin and the oncogenic translocation product, CALMAF10. There are multiple break points within AF10 observed in CALM-AF10 positive
leukemia cells, leading to variability in which domains are retained or lost (Figure 1) [49,
113]. The minimal domain in all translocations includes the OM/LZ domain, but the
breakpoint can occur as N-terminal as within the PZP region (Figure 1) [50]. The CALMAF10 construct used in this study was designed based on the original cloning of CALMAF10 by Dreyling, et. al. in 1996 [15]. This breakpoint occurs within the PZP region, which
has been shown to be involved in protein-protein interaction, particularly the interaction
between AF10 and FLRG [84]. It is probable that b-Catenin would also interact with this
PZP region of AF10, though further validation is necessary to confirm the exact domain.
Because this CALM-AF10 construct represents the most generous amount of AF10
retained in a translocation, we would hypothesize that regardless of breakpoint location,
this interaction between AF10 and b-Catenin would not occur in CALM-AF10 leukemia
cells.
These results are preliminary, however, as the pull-down of CALM-AF10 to
investigate the interaction between CALM-AF10 and b-Catenin was only repeated once
and the converse immunoprecipitation of b-Catenin has not yet been performed. Previously
in the lab, we have performed preliminary b-Catenin immunoprecipitations and observed
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co-IP of AF10. This would give credibility to the results of the same b-Catenin IP and
subsequent blot for CALM-AF10, if repeated in triplicate and no interaction was shown.
Additionally, we also have an HA-tagged CALM-AF10 expressing plasmid available,
which we would utilize in parallel experiments to confirm or deny the present results. If
these experiments all uniformly indicated a lack of interaction between CALM-AF10 and
b-Catenin, it would be appropriate to accept that conclusion. Even so, we take the data at
hand to speculate mechanisms of what is occurring in the cell.
AF10 has been shown to be required for proper transcription of b-Catenin/Wnt target genes
[85]. The implication that CALM-AF10 does not interact with b-Catenin has several
inferences for what could be occurring mechanistically in CALM-AF10 leukemias. First,
there is haploinsufficiency of wild type AF10. Regardless of the presence of CALM-AF10,
the paucity of wild type AF10 could hinder the cells’ transcription of Wnt target genes after
Wnt stimulation. Considering then, that CALM-AF10 does not retain the ability to interact
with b-Catenin and thus be recruited to TCF/LEF target genes, we would expect to see a
decrease in transcription of these genes.

CALM-AF10 upregulates HEK293T-7xTFP cells’ response to Wnt3a
The results of three biological replicates indicated that, upon addition of 0.5 µg and
1 µg CALM-AF10 into our HEK293T-7xTFP cell system, CALM-AF10 resulted in
upregulated luciferase expression compared to MIE transfected and no-DNA parental cells
(Figure 7). The results were validated by the significant decrease observed in luciferase by
TCF4∆N31; this construct inhibited TCF target gene transcription in a dominant negative
fashion, deterring b-Catenin from localizing to the plasmid 7xTCF binding sites.
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These results were surprising, given our finding that CALM-AF10 does not interact
with b-Catenin. We had anticipated that loss of this interaction would result in a decrease
in transcription, as b-Catenin would not be able to recruit the transcriptionally activating
CALM-AF10 fusion protein to its target genes. Upregulation in Wnt signaling, per our
original hypothesis, would have been due CALM-AF10 recruitment to Wnt target genes
via a conserved interaction between AF10 and b-Catenin.
An example of how aberrant localization and activation of oncogenic target genes
by CALM-AF10 occurs, is through interaction with the Hoxa cluster, although here it is
the interaction between CALM and XPO1 which localizes CALM-AF10 [46, 117]. This is
a well-established mechanism of how fusion proteins alter transcription: One fusion partner
causes the aberrant recruitment to an oncogenic gene, and the other fusion partner alters
levels of transcription at that locus [20]. CALM has a transactivation domain, so we had
expected the recruitment of CALM-AF10 by b-Catenin to result in a higher level of
transcription than AF10 alone. However, we observed that CALM-AF10 is leading to the
upregulated transcription of Wnt target genes even though the interaction between CALMAF10 and b-Catenin seems to be lost in the fusion protein. There are several possible
reasons for why this could be occurring.

Potential Mechanisms for Upregulated Wnt Transcription (Figure 8)
We have hypothesized that, based on the loss of interaction between CALM-AF10 and bCatenin, CALM-AF10 is not recruited to TCF target genes in the same b-Catenindependent manner that is observed with AF10 [85]. It has been shown that AF10 forms
higher order complexes in vitro, so it is highly possible that CALM-AF10 complexes with
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wild type AF10. In a leukemic cell with only one wild type allele of AF10, this may result
in a sequestration effect of AF10. CALM-AF10 shuttles its interacting partners to the
cytoplasm via the nuclear export signal within CALM, as characterized both with IKAROS
and DOT1L [52, 150]. However, our experimental system fails to mimic
haploinsufficiency of AF10 as both alleles in the HEK293T cells are intact. This could
mean that there is sufficient AF10 in the nucleus to retain its binding to gene targets, and
in fact, could lead to CALM-AF10-AF10 complexes localizing to b-Catenin target genes
through wild type AF10 activity. Even though CALM-AF10 itself does not interact with
b-Catenin, the transcriptional effects of this would be masked by enough wild type AF10.
AF10 could therefore recruit the oncogene to its gene targets by forming oligomeric
complexes, in a manner not yet defined by the literature.
Alternatively, CALM-AF10 could be having an indirect effect on TCF target gene
expression by binding to and regulating genes which in turn, regulate the cells’ response to
Wnt signaling. For example, CALM-AF10 could be directly upregulating b-Catenin levels,
allowing for a secondary increase in TCF/b-Catenin target gene expression as a result. Our
experimental set up involved transfecting cells with our constructs for twenty-four hours
prior to stimulation with Wnt3a, and then they are stimulated for another twenty-four hours.
That is enough time for indirect, downstream effects of CALM-AF10 to manifest as
alterations in transcription [157]. Per our dose-response curve generated in figure 4B, the
most robust response to Wnt3a occurred after 18 or 24 hours. However, there was still a
dose-dependent upregulation in luciferase expression after 6 hours, so to test this, we would
shorten the timeline of the experiment to minimize downstream effects of CALM-AF10.
This would help us parse out whether our observation was due to an indirect effect of
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CALM-AF10 binding to non-TCF target genes, involved in regulating the Wnt
transcriptional response.
Specifically, it has been documented that CALM-AF10 both leads to an upregulation of
the Polycomb Repressive Complex (PRC) member, B-lymphoma Moloney murine
leukemia virus insertion region-1 (BMI-1), and is dependent on it [118, 158]. This
repressive oncogene is involved in many human cancers, playing a role in self-renewal and
proliferation of cancer stem cells [159-161]. BMI-1 has been shown to activate Wnt
signaling by repressing transcription of DKK1, a Wnt inhibitor [162]. This BMI-1-driven
downregulation of DKK1 lead to activation of Wnt target, c-MYC, which independently
promotes further transcription of BMI-1 in a feed-forward mechanism [162]. This is an
interesting connection between our findings and those previously reported, and could
explain why we observed upregulated Wnt signaling in the absence of a b-Catenin-CALMAF10 interaction.

Figure 8: Schematic representing hypothesized and possible mechanisms of Wnt alteration via CALM-AF10. (A)
Represents normal AF10 localization to TCF target genes in a b-Catenin dependent manner. (B) Represents the
hypothesized mechanism of CALM-AF10 action in a leukemia cell; due to haploinsufficiency of AF10, there is a decrease
in Wnt target gene transcription because CALM-AF10 would not be recruited to TCF target genes via b-Catenin. (C)
One possible explanation of upregulated Wnt signaling in light of lost interaction between AF10 and b-Catenin: sufficient
AF10 in the HEK293T cell system leads to oligomerization between AF10 and CALM-AF10, thereby recruiting CALMAF10 to TCF target genes via WT AF10 interacting with b-Catenin. (D) Another proposed mechanism whereby CALMAF10 leads to the upregulation of Wnt target genes in the absence of a functional interaction with b-Catenin: CALMAF10 could bind and upregulate genes involved in the regulation of Wnt signaling, leading to an indirect effect on Wnt
signaling.
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Future directions, Limitations, and Other Considerations
The future directions of this project encompass two avenues: validating and
uncovering the biochemical mechanism for this phenomenon, and exploring what our
results mean phenotypically for a leukemic cell. I will first touch on the avenues for which
the biochemical mechanism would be further explained.
Foremost, it is important to understand some of the obvious limitations of this
study. This thesis sought to determine the effect CALM-AF10 has on Wnt signalingmediated transcription, and explore the mechanism by which the effect occurs. An
underlying issue in this body of work is the timing of this research within current events;
namely the SARS-CoV2 pandemic leading to the closure of labs, prohibiting replication of
some results and hindering progress of future directions. This discussion takes the
limitations of this research into consideration, drawing no definitive conclusions and
detailing the future of this work to be carried out after the lab resumption.
The immunoprecipitation experiments have only been repeated once, and need to
be replicated in triplicate. The luciferase results, while the outcome of three biological
replicates, should be validated by another method before conclusions are drawn. We will
perform qPCR at confirmed Wnt target genes in HEK293T cells, with a similar
experimental setup to confirm an upregulation in response to CALM-AF10. Following this
validation, we will move forward to expand the understanding of this phenomenon.
As briefly mentioned, it will be important to determine if CALM-AF10 and AF10
form a complex together. To investigate this, we would pull down FLAG-CALM-AF10
with an anti-FLAG antibody, and immunoblot for wild type AF10, expecting that they will
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interact. This can be confirmed with another CALM-AF10 construct that our lab has, HAtagged CALM-AF10. If this interaction is confirmed, it provides credibility to both
abovementioned hypotheses explaining how Wnt signaling is upregulated. From there, we
can take steps to further parse out the two mechanisms.
We would perform Chromatin Immunoprecipitation (ChIP) coupled to qPCR, of
FLAG- and HA-CALM-AF10 at several gene targets in HEK293T cells. These would
include TCF target genes, such as Axin2 and c-Myc, as well as Bmi-1. These results would
better indicate how CALM-AF10 is leading to upregulated Wnt signaling, whether it be
direct localization to TCF target genes through the action of sufficient wild type AF10, or
indirectly through binding and upregulation of the Bmi-1 gene. Even if CALM-AF10 does
not directly bind any of those three gene loci, we could repeat our luciferase experiments
with BMI-1 inhibitors to identify if inhibiting BMI-1 leads to an abrogation of the effect
we observed.
Additionally, we want to determine if this upregulated Wnt transcription is unique
to CALM-AF10. We would repeat these experiments, and/or validate results by qPCR,
with other AF10 fusion proteins, as well as the related HOXA9-MEIS1 fusion oncoprotein
which upregulates Hoxa expression by an alternative mechanism to CALM-AF10. This
would give us an idea of whether Wnt signaling upregulation is specifically and
mechanistically due to CALM-AF10, or is broadly activated by a variety of oncogenic
fusion proteins.
It is interesting to note that, given the importance of dysregulated Hoxa gene
expression in leukemia, there is known interplay between Wnt signaling and Hox gene
expression. There is significant evidence indicating a relationship between the Hox genes
41

and Wnt signaling throughout embryonic development, and one study determined that
there is a Wnt-dependent enhancer within the 3’ subtopologically associated domain
(subTAD) of the Hoxa genes [163-167]. This study showed that, after pregastrula epiblasts
lacking Wnt3a were exposed to a Wnt agonist, the Hoxa genes were activated in the same
spatiotemporal manner as occurs in vivo [163].
Wnt signaling has been shown to provide appropriate spatiotemporal and
contextual activation of Hox genes in C. elegans neuroblast migration [165]. Additionally,
during collective cell migration of zebrafish embryogenesis, the CXCR4b chemokine
receptor is dependent on HOXb8a activity, which is reliant upon Wnt signaling [166]. This
is of interest in the context of leukemia, as upregulation of adhesion molecules can lead to
chemotherapy resistance and relapse [168]. However, there is a large disconnect between
what is known of these major cell-fate determination pathways during embryogenesis
verses in the context of leukemia, and further studies could better determine the interplay
of aberrant Wnt signaling and Hoxa gene expression.
Clinically, it becomes of great interest to determine if and how Wnt signaling is
modulated in CALM-AF10 leukemias for a therapeutic benefit. If our observed
phenomenon of upregulated Wnt signaling is validated, then we can begin to expand our
understanding of how CALM-AF10 leukemias take advantage of this signaling pathway,
resulting in a high-risk leukemia. The future directions of this project encompassing
clinically translatable aims, include pursuing targeted therapeutic studies in leukemia cells.
Here we would ask the question if Wnt inhibition selectively kills CALM-AF10 leukemia
cells in vitro, in combination with chemotherapy or alone. If promising, these studies could
then be performed in mice with CALM-AF10 leukemia. This would identify the
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significance of aberrant Wnt signaling in these cancers, and provide evidence for or against
the therapeutic benefit of manipulating Wnt signaling for therapeutic benefit in patients.
The results of these studies will allow us to provide significant results for the broad
scientific community looking to better understand leukemia, in hopes of bettering the
outcomes of those affected by it.

Concluding remarks
This thesis sought to determine how the oncogenic fusion protein, CALM-AF10,
alters Wnt signaling with regards to leukemia. We devised a system in which to measure
transcriptional alterations in Wnt-target gene transcription in HEK293T cells by the
addition CALM-AF10, and the results of our study indicated that CALM-AF10 upregulates
Wnt target gene expression in this context. We also obtained preliminary data indicating
that the interaction between CALM-AF10 and b-Catenin does not occur in vitro. The
results of our study warrant validation, but excitingly open the door for avenues of research
to identify mechanisms, with potential clinical translation.
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Materials and Methods
Cell culture technique
HEK293T cells were grown in Dulbecco’s (MEM) supplemented with 5% FBS, L-glutamine, 1%
Pen/Strep, NEAA and sodium pyruvate. HEK293T-7xTFP cells were grown in the same media
with 1 µg/mL puromycin for selection, and 0.5 µg/mL for maintenance. Kasumi-1 cells were
maintained in RPMI with 20% FBS, 1% Pen/Strep, and 1% Non-essential amino acids (NEAA).

Western Blot
Samples were harvested with 200 µL protein lysis buffer (1% Triton X-100, 2 mM
EDTA, 1 mM DTT in PBS), incubated on ice for 20 minutes, and centrifuged at 18,000 x
g for 5 minutes at 4˚C. Supernatant was isolated and quantified with the Pierce BCA
Protein Assay Kit. 5X Protein loading buffer was added to samples (10% SDS, 0.5M
DTT, 50% Glycerol, 0.5M Tris-HCl, 0.05% bromophenol blue) before boiling for ten
minutes. Samples were cooled to room temperature before being stored at -20˚C or
running on 8% resolving SDS-PAGE gel with a 5% stacking layer. Gels were
electrophoresed at 120V for 1:30:00. Protein samples were then transferred onto PDVF
membranes (ThermoScientific) and transferred for 2:00:00 at 100V at 4˚C. Blots were
blocked with 5% milk in TBST, and blotted at 4˚C overnight with an anti-PICALM
antibody (Sigma, HPA-019053, Rabbit) or anti-GAPDH (CST, 14C10, Rabbit) at 1:1000
in 3% or 5% milk in TBST, respectively. Blots were developed using BioRad Clarity
Western ECL substrate, and imaged using the BioRad Chemi-DocTM XRS+ Imaging
System.
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Co-Immunoprecipitation and Pull-Down Techniques
For pull-down of CALM-AF10, HEK293T cells were transiently transfected in ten cm
plates by calcium phosphate with 1 µg CALM-AF10 or MIE empty vector control. 48
hours after transfection, cells were harvested with 1 mL protein lysis buffer (1% Triton
X-100, 2 mM EDTA, 1 mM DTT in PBS). Samples were incubated on ice for 20
minutes, and centrifuged at 18,000 x g for 5 minutes. Clarified supernatant was
quantified, and incubated with an M2 anti-FLAG antibody (Millipore Sigma, mouse), and
25 µL Protein A/G magnetic beads (Pierce) overnight at 4˚C. The beads were washed 4x
with fresh protein lysis buffer and 2x Laemmli buffer (4% SDS, 20% Glycerol, 120 mM
Tris-Cl pH 6.8) was added before samples were boiled briefly (4 min). Eluate was
isolated from the beads and subject to SDS-PAGE (see Western Blot methods).
Membranes were blotted with an anti-PICALM antibody (Sigma, HPA-019053, Rabbit).
For Kasumi-1 immunoprecipitation of AF10, 1x106 Kasumi-1 cells were collected, rinsed
2x in PBS, and harvested with protein lysis buffer. Samples were prepared as above and
antibodies added at 2 µg per mg of cell lysate. Antibodies used were AF10 (Abcam,
HAF10 9A5/2, mouse) or mouse IgG isotype control (CST, G3A1), with 25 µL Protein
A/G beads (Pierce) before overnight rotation at 4˚C. Samples were washed, eluted and
electrophoresed as described above, membranes were blotted with AF10 (Sigma, HPA005747, Rabbit) and b-Catenin (Thermo Fisher, PA5-77934, Rabbit)

Development of HEK293T-7TFP stable reporter cell lines
The 7TFP Wnt reporter plasmid has a 7xTcf-FFluc (firefly luciferase) reporter cassette,
and puromycin resistance downstream from an SV40 promoter for selection of infected
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cells [153]. HEK293T cells were transfected with XtremeGene HP, following the
manufacturer’s protocol. 5 days post transfection, infected cells were selected for with 1
µg/mL puromycin for one week based on the results of a puromycin kill curve. Selection
maintenance occurred at 0.5 µg/mL puromycin. Single clones were achieved with
limiting dilution, and daily observation to ensure single cell origin of growing clones.

Luciferase assay
HEK293T-7TFP cells were plated for transfection at 5x105 cells/well in a 6-well plate on
day 0. On Day 1, cells were transfected by calcium phosphate, with a total of 2 µg DNA
for CALM-AF10 and MIE conditions. 4µg of the TCF4∆N31 control plasmid was
transfected. Fresh media replaced transfection media 5 hours after transfection, and cells
were stimulated with 100ng/mL Wnt3a ligand 24 hours after transfection. 2 ng/mL
Doxycycline was added to the TCF4∆N31 condition at this time. 48 hours after
transfection, cells were harvested; 5x105 cells were counted and harvested for luciferase
assay using BioVision Luciferase Reporter Assay Kit lysis buffer (Catalogue # K801),
the remainder for western blot analysis. Luciferase assay was carried out per the
manufacturer’s protocol in triplicate, using the Perkin Elmer VICTOR X4 multimode
plate reader and dispenser. Resulting counts (5 seconds) were normalized to baseline
counts. The resulting values from Wnt3a added conditions were normalized to the
conditions without Wnt3a, and all conditions were normalized to the parental condition.
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